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Abstracts
patients with at least one antipsychotic prescription be-
tween 5/1 and 7/31/1995. A patient's first antipsychotic
prescription (the index prescription) during this interval
was used to classify each patient into an atypical or a typ-
ical antipsychotic cohort. Patients were further classified
into "new" or "continuing" cohorts based on whether or
not the patients had received any antipsychotic prescrip-
tions during the 12-month period preceding their index
prescriptions. Duration of continuous therapy, defined as
the total number of antipsychotic days supplied to a pa-
tient prior to a period of 31 or more days with no anti-
psychotic medications, was tracked over a two-year pe-
riod after the index prescription.
RESULTS: Duration of continuous therapy was 201 :!::
266 (rnean z. SD) days for all patients. For atypical anti-
psychotics, the duration of continuous therapy was 301
:!:: 299 days for new users and 347 :!:: 308 days for con-
tinuing users. In contrast, the duration of continuous
therapy for typical antipsychotics was 136 :!:: 229 days
for new users and 257 :!:: 278 days for continuing users.
CONCLUSION: Patients on atypical antipsychotics have
a longer duration of continuous therapy.
MONTH-TO-MONTH ADHERENCE WITH
ANTIPSYCHOTIC PHARMACOTHERAPY:
A COMPARISON BETWEEN ATYPICAL
AND TYPICAL ANTIPSYCHOTICS
Li ZI, Hutchins DS', Johnstone BM2, Tunis SL2, Coleman TR2,
Gevirtz F'
'PCS Health Systems Inc., Scottsdale, AZ, USA;"Eli Lilly and
Company, Indianapolis, IN, USA
Adherence to antipsychotic therapy is associated with
greater likelihood of positive outcomes for schizophrenia
treatment. Atypical antipsychotic agents, with broader
response profiles and greater tolerability, may increase
the probability of compliance with drug therapy relative
to typical antipsychotic agents.
OBJECTIVE: This study compares month-to-month ad-
herence to pharmacotherapy between atypical and typical
antipsychotics in the naturalistic care setting.
METHODS: Claims from a large U.S. prescription data-
base were analyzed for 56,682 patients who received at
least one antipsychotic prescription between 5/1 and 7/31/
1995. A patient's first antipsychotic prescription (the in-
dex prescription) during this interval was used to classify
the patient from an intent-to-treat perspective as an atyp-
ical or typical antipsychotic user. Month-to-month ad-
herence to pharmacotherapy for 32,066 patients who did
not receive an antipsychotic prescription during the 12-
month period preceding their index prescriptions were
tracked over a two-year period following their index pre-
scriptions. Month-to-month adherence on drug therapy
was measured as possessing at least 15 days of the same
antipsychotic within a 3D-day period.
RESULTS: Almost all (97%) atypical antipsychotics re-
cipients successfully completed at least one month of
81
compliance on pharmacotherapy, compared to only half
(53%) of recipients on typical antipsychotics. At the 6th
month, 54% of atypical and 26% of typical antipsychotic
recipients were compliant. These percentages declined to
45% and 22% at the 12th month, 40% and 19% at the
18th month, and 11 % and 5 % at the 24th month for
atypical versus typical antipsychotic recipients, respec-
tively.
CONCLUSION: Measured over a maximum of 24
months, patients on atypical anti psychotics were more
likely to adhere on a month-to-month basis with antipsy-
chotic therapy.
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OBJECTIVE: The purpose of this study was to assess the
impact of commonly applied research selection criteria on
the proportion of patients initiated on fluoxetine, parox-
etine, or sertraline who received only the initial agent, at
the same dose, for 90 or more continuous days.
METHODS: This retrospective utilization analysis of a
large u.s. prescription claims database grouped patients
initiating on fluoxetine, paroxetine, or sertraline into
samples with (typical design, n = 17,825) and without
(relaxed design, n = 291,758) commonly applied re-
search selection criteria. Patients selected were 18 or
older and eligible during the respective review periods.
Patients in the typical design had no prior period use of
antidepressants and no use of other psychotropics. Pa-
tients who maintained 90 or more continuous days of
therapy exclusively on their initial study drug and who
did not experience dose escalation were assigned a stable
utilization pattern. All others were assigned a non-stable
utilization pattern.
RESULTS: The typical design had significantly (p :s
0.001) fewer patients with a stable utilization pattern
(29% typical, 32% relaxed). The percentage of patients
achieving a stable utilization pattern with fluoxetine was
at least five percentage points greater, a significant (p :S
0.001) difference, than the percentage for either paroxet-
ine or sertraline. The stable pattern was significantly
more likely for sertraline than paroxetine patients in the
relaxed design (29.7%, 29.1 %, p = 0.017) but not in the
typical design (26.5%,26.6%, p = 0.920).
CONCLUSIONS: A stable utilization pattern is more
likely with fluoxetine than with paroxetine or sertraline
initiated patients. The stable pattern's relative relation-
ship is robust across designs for fluoxetine but not for
paroxetine and sertraline.
